Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Now accepting nominations for the Fierce Innovation Awards - Submit your application today
Gilead Sciences
Pharma
Gilead's Yeztugo faces growth outlook questions
Despite Yeztugo's quarterly revenue beat, Gilead has kept the PrEP drug's 2026 forecast unchanged at about $1 billion.
Angus Liu
Aug 5, 2026 10:44am
Gilead prevails in yearslong HIV drug innovation case
Aug 4, 2026 3:00pm
Gilead uses humor in ‘Up to Date’ HIV prevention push
Jul 28, 2026 8:00am
Gilead, Merck phase 3 data back first weekly HIV pill
Jul 21, 2026 10:00am
Gilead gets wild in bronze-winning Cannes spot
Jul 16, 2026 9:18am
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC
Jun 24, 2026 5:00pm
